Profile: Abbott Laboratories (ABT.N)
18 Jan 2019
Abbott Laboratories, incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Company, through St. Jude Medical, Inc., also offers a range of products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
The principal products in the Company's other businesses include blood glucose and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes, under the FreeStyle brand, and medical devices for the eye, including cataract surgery, laser-assisted in situ keratomileusis (LASIK) surgery, contact lens care products and dry eye products. These products are marketed around the world and sold to wholesalers, government agencies, private healthcare organizations, healthcare facilities, mail order pharmacies, and independent retailers from its distribution centers and public warehouses.
Established Pharmaceutical Products
The Company's Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. These products are sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from its distribution centers and public warehouses, depending on the market served. The principal products included in the therapeutic area of the Established Pharmaceutical Products segment are gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines.
The gastroenterology products include Creon, which is used for the treatment of pancreatic exocrine insufficiency associated with various underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal and Dicetel, which is used for the treatment of irritable bowel syndrome or biliary spasm; Heptral, Transmetil and Samyr, which is used for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms, and Duphalac, which is used for regulation of the physiological rhythm of the colon. Its women's health products include Duphaston, which is used for the treatment of various gynecological disorders, and Femoston, which is a hormone replacement therapy for postmenopausal women.
The cardiovascular and metabolic products include Lipanthyl and TriCor, which is used for the treatment of dyslipidemia; Teveten and Teveten Plus, which is used for the treatment of essential hypertension; Physiotens, which is used for the treatment of hypertension, and Synthroid, which is used for the treatment of hypothyroidism. Its pain and central nervous system products include Serc, which is used for the treatment of Meniere's disease and vestibular vertigo; Brufen, which is used for the treatment of pain, fever and inflammation, and Sevedol, for the treatment of severe migraines. Its respiratory drugs and vaccines include the anti-infective clarithromycin, which are sold under the brands Biaxin, Klacid, and Klaricid, and Influvac, which is an influenza vaccine.
The Company's Diagnostic Products include a range of diagnostic systems and tests manufactured, marketed, and sold around the world. These products are marketed and sold to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate care testing sites and plasma protein therapeutic companies from its distribution centers, public warehouses or third party distributors. The principal products in the Diagnostic Products segment include immunoassay and clinical chemistry systems, including ARCHITECT, ABBOTT PRISM, and the Alinity family of instruments, with assays used for screening and/or diagnosis for cancer, cardiac, metabolics, drugs of abuse, fertility, general chemistries, infectious diseases, such as hepatitis and human immunodeficiency virus (HIV), and therapeutic drug monitoring; a range of hematology systems and reagents known as the Cell-Dyn series; the i-STAT and i-STAT Alinity point-of-care diagnostic systems and cartridges for blood analysis; m2000, which is an instrument that automates the extraction, purification, and preparation of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from patient samples, and detects and measures infectious agents; the Vysis FISH product line of genomic-based tests, including the PathVysion Human Epidermal Growth Factor Receptor 2 (HER-2) DNA probe kit, the UroVysion bladder cancer recurrence kit, and the Vysis ALK Break Apart FISH Probe Kit, and informatics and automation solutions for use in laboratories, including ACCELERATOR a3600, and AlinIQ, a range of informatics tools and professional services.
The Company's Nutritional Products include a range of pediatric and adult nutritional products manufactured, marketed and sold around the world. These products are marketed and sold to consumers and to institutions, wholesalers, retailers, healthcare facilities, government agencies, and third-party distributors from its distribution centers or third-party distributors. The products in the Nutritional Products segment include various forms of prepared infant formula and follow-on formula, including Similac, Similac Pro-Advance, Similac Advance, Similac Pro-Sensitive, Similac Sensitive, Go&Grow by Similac, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Similac For Supplementation, Isomil Advance, Similac Qinti and Eleva; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Enlive, Ensure Complete, Ensure High Protein, Glucerna, Glucerna Hunger Smart, ProSure, PediaSure, PediaSure Sidekicks, PediaSure Peptide, EleCare, Juven, Abound and Pedialyte; nutritional products, which are used in enteral feeding in healthcare institutions, including Jevity, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, Nepro, and Vital, and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge.
The Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease that are manufactured, marketed and sold around the world. In the United States, these products are marketed and sold to hospitals from its distribution centers and public warehouses. The products in the Vascular Products segment include the XIENCE family of drug-eluting coronary stent systems developed on the Multi-Link Vision platform; StarClose SE and ProGlide vessel closure devices; TREK coronary balloon dilatation products; Hi-Torque Balance Middleweight Universal and ASAHI coronary guidewires; MitraClip, which is a percutaneous mitral valve repair system; Supera Peripheral Stent System, which is a peripheral vascular stent system, and Acculink/Accunet, and Xact/Emboshield NAV and carotid stent systems.
100 Abbott Park Rd
ABBOTT PARK IL 60064-3500
Company Web Links
- Abbott resolves N.Y. claims over misleading infant-feeding surveys
- Abbott, AbbVie settle TriCor marketing case for $25 million
- UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln
- Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln
- Abbott Labs quarterly profit falls on higher tax expense